CD95L pro-drug: A novel Swiss Army Knife in cancer therapy?

Cell Death and Differentiation

Volumn 14, Issue 3, 2007, Pages 393-394

  Kassahn, D ^a   Nachbur, U ^a   Brunner, T ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD95 LIGAND; DEATH RECEPTOR; FAS ANTIGEN; LIGAND; ONCOPROTEIN; PROTEINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER THERAPY; COMBINATION CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG ACTIVATION; DRUG EFFICACY; DRUG INACTIVATION; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; NOTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; UPREGULATION;

ANTIGENS, CD95; ANTIGENS, NEOPLASM; APOPTOSIS; DRUG DESIGN; FAS LIGAND PROTEIN; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; PEPTIDE HYDROLASES; T-LYMPHOCYTES;

EID: 33847039084     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402069     Document Type: Note

References (10)

1. Locksley RM et al. Cell 2001; 104: 487-501.
2. Overall CM, Dean RA. Cancer Metastasis Rev 2006; 25: 69-75.
3. Nachbur U et al. Blood 2006; 107: 2790-2796.
4. Loo G et al. Cytokine 2003; 22: 62-70.
5. Ogasawara J et al. Nature 1993; 364: 806-809.
6. Jung G et al. Cancer Res 2001; 61: 1846-1848.
7. Aoki K et al. Mol Ther 2000; 1: 555-565.
8. Hopkins-Donaldson S et al. Cell Death Differ 2003; 10: 356-364.
9. Cefai D et al. Cell Death Differ 2001; 8: 687-695.
10. el-Deiry WS. Semin Cancer Biol 1998; 8: 345-357.